Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VLX-1005 in suspected heparin-induced thrombocytopenia
NCT05785819Phase 2Terminated
- Sponsor
- Veralox Therapeutics
- Start
- Sep 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heparin-induced thrombocytopenia (HIT) comparing VLX-1005 + Standard of Care with Placebo + Standard of Care (2 arms). Primary endpoint: Time to recovery of platelet count to ≥150×10^9/L in patients with positive serotonin release assay up to 14 days. Started Sep 2023; status: terminated.
02
Drugs
VLX-1005
03
Conditions
heparin-induced thrombocytopenia (HIT)
Beyond the preview
Go deeper on NCT05785819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05785819.